Utility of serum cystatin C measured at diagnosis in evaluating cross-sectional activity and predicting all-cause mortality in patients with antineutrophil cytoplasmic antibody-associated vasculitis
Clinical Rheumatology · 2025
DOI: 10.1007/s10067-025-07753-w ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Clinical Rheumatology, 2025. Verfasst von Hyeok Chan Kwon und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Republic of Korea. Hauptthemen laut MEDLINE: Cystatin C, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION/OBJECTIVES: We investigated the utility of serum cystatin C (CysC) at diagnosis in evaluating cross-sectional activity and predicting all-cause mortality (ACM) during follow-up in patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV). METHODS: We retrospectively reviewed the medical records of 323 patients with AAV enrolled in a single-centre cohort of Korean patients and included 109 patients meeting the inclusion criteria. The Birmingham Vasculitis Activity Score (BVAS) and Five-Factor Score (FFS) were used for assessing AAV activity and anticipating prognosis. ACM alongside end-stage kidney disease during follow-up were investigated as poor outcomes. RESULTS: The median age of the 109 patients was 66.0 years, with 45.0% being male. Among them, 77, 17, and 15 had MPA, GPA, and EGPA, respectively. Serum CysC at diagnosis exhibited a significant positive correlation with cross-sectional BVAS, alongside age and FFS. When the cut-off of serum CysC for ACM was set at 2.56 mg/L, patients with serum CysC ≥ 2.56 mg/L at diagnosis had a significantly higher relative risk of ACM during follow-up than those without (10.988). Patients with serum CysC ≥ 2.56 mg/L at diagnosis exhibited a significantly lower cumulative survival rate compared to those without. In multivariable Cox proportional analysis, serum CysC ≥ 2.56 mg/L at diagnosis (hazard ratio 5.994) remained independently associated with ACM during follow-up alongside male sex and BVAS at diagnosis. By contrast, serum creatinine was not significantly associated with ACM, suggesting that CysC may provide incremental prognostic value beyond conventional renal indices. CONCLUSION: This study is the first to demonstrate the potential clinical utility of serum CysC at diagnosis in assessing cross-sectional disease activity and predicting ACM during follow-up in AAV patients independently of baseline kidney function. These findings are preliminary and should be validated in larger prospective cohorts. Key Points • Serum cystatin C measured at diagnosis was significantly associated with disease activity in antineutrophil cytoplasmic antibody-associated vasculitis (AAV). • Cystatin C levels reflected systemic inflammation beyond the effect of baseline renal function. • A cystatin C level ≥2.56 mg/L independently predicted all-cause mortality during follow-up. • This study is the first to demonstrate the prognostic value of serum cystatin C in patients with AAV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Republic of Korea.
- Division of Rheumatology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Gyeonggi-Do, Republic of Korea.
- Division of Rheumatology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Division of Rheumatology, Department of Internal Medicine, Shinchon Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Division of Rheumatology, Department of Internal Medicine, Shinchon Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea. SANGWONLEE@yuhs.ac.
Zitieren
APA
Kwon, H. C., Ha, J. W., Kwon, O. C., Park, Y. B., & Lee, S. W. (2025). Utility of serum cystatin C measured at diagnosis in evaluating cross-sectional activity and predicting all-cause mortality in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Clinical Rheumatology. https://doi.org/10.1007/s10067-025-07753-w
Vancouver
Kwon HC, Ha JW, Kwon OC, Park YB, Lee SW. Utility of serum cystatin C measured at diagnosis in evaluating cross-sectional activity and predicting all-cause mortality in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Clinical Rheumatology. 2025. doi:10.1007/s10067-025-07753-w
BibTeX
@article{Kwon2025,
author = {Kwon, Hyeok Chan and Ha, Jang Woo and Kwon, Oh Chan and Park, Yong-Beom and Lee, Sang-Won},
title = {Utility of serum cystatin C measured at diagnosis in evaluating cross-sectional activity and predicting all-cause mortality in patients with antineutrophil cytoplasmic antibody-associated vasculitis},
journal = {Clinical Rheumatology},
year = {2025},
doi = {10.1007/s10067-025-07753-w}
}
EUVIMED